F040 Respect the Dormant Beast: Optimize Your Management of High-Risk Cutaneous SCCs
DESCRIPTION
Approximately 5% of cutaneous SCCs (cSCCs) harbor high-risk features. The rate of nodal metastasis and disease-specific death for cSCCs are 4% and 1.5%, respectively. Identification and management of high-risk cSCCs can be challenging and is a dynamic field. This session will offer tips on diagnosis and management through two parts. Part A will consist of clinical pearls from experts on management of high-risk cSCCs with a focus on prognostics, surgery, radiologic staging and surveillance, and prevention. Part B will consist of case based presentations from multidisciplinary experts from across the world.
LEARNING OBJECTIVES
Recognize clinical, histological and molecular features of high-risk cSCCs, and review outcomes and limitations of current staging systems and gene expression profiling.
Outline opportunities to improve management of cSCCs based on tumor risk stratifications and host factors, using field therapy, radiologic and nodal staging, neoadjuvant therapy, and post-operative adjuvant therapy.
Discuss advances in the management of cSCCs in solid organ transplant recipients.
SCHEDULE
1:05 PM
CSCC Staging and Prognostics
Nina Ran, MD, MS, FAAD
1:17 PM
Surgical Management of High-Risk CSCCs
Justin J. Leitenberger, MD, FAAD
1:29 PM
Radiologic Staging and Surveillance
Kathryn Shahwan, MD, FAAD
1:41 PM
Optimizing CSCC prevention
Anokhi Jambusaria-Pahlajani, MD, MS, FAAD
2:00 PM
Top 3 Cases from Spain
Javier Cañueto
2:12 PM
Top 3 Cases from a Medical Oncologist
Justine Cohen, DO
2:24 PM
Top 3 Cases from Washington DC
Vishal Patel, MD
2:36 PM
Top 3 Cases from Boston
Emily S Ruiz, MD, FAAD
DIRECTOR
Emily S Ruiz, MD, FAAD
SPEAKERS
Javier Cañueto
Justine Cohen, DO
Anokhi Jambusaria-Pahlajani, MD, MS, FAAD
Justin J. Leitenberger, MD, FAAD
Vishal Patel, MD
Nina Ran, MD, MS, FAAD
Kathryn Shahwan, MD, FAAD
DISCLOSURES
Javier Cañueto
No financial relationships exist with ineligible companies.
Justine Cohen, DO
Bristol-Myers Squibb – Advisory Board(Honoraria); Replimune – Advisory Board(Honoraria);
Anokhi Jambusaria-Pahlajani, MD, MS, FAAD
Regeneron Pharmaceuticals, Inc. – Advisory Board(Honoraria); Sun Pharmaceutical Industries Ltd. – Advisory Board(Honoraria);
Justin J. Leitenberger, MD, FAAD
No financial relationships exist with ineligible companies.
Vishal Patel, MD
Almirall – Speaker(Honoraria); Gerson Lehrman Group – Consultant(Fees); Regeneron – Speaker(Honoraria); Regeneron Pharmaceuticals, Inc. – Advisory Board(Honoraria), Investigator(Grants/Research Funding); Sun Pharmaceutical Industries Ltd. – Advisory Board(Honoraria), Speaker(Honoraria);
Nina Ran, MD, MS, FAAD
Chronicle Medical Software – Consultant (1099 relationship)(Fees);
Emily S Ruiz, MD, FAAD
Almirall – Consultant (1099 relationship)(Fees); Castle Biosciences, Inc – Investigator(Grants/Research Funding); Checkpoint Therapeutics – Consultant (1099 relationship)(Fees); Feldan Therapeutics – Consultant (1099 relationship)(Fees); Merck – Investigator(Grants/Research Funding); Regeneron – Advisory Board(Fees), Investigator(Grants/Research Funding); Sun Pharmaceutical Industries Ltd. – Advisory Board(Fees), Consultant (1099 relationship)(Fees);
Kathryn Shahwan, MD, FAAD
No financial relationships exist with ineligible companies.